跳至主要内容
临床试验/NCT00267384
NCT00267384已完成2 期

N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity

Soroka University Medical Center2 个研究点 分布在 1 个国家开始时间: 2006年3月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
2
主要终点
The decrease in glomerular filtration rate (GFR)

研究概览

简要总结

This randomized, double-blind, placebo-controlled clinical trial will be performed to assess the effect of N-acetylcysteine therapy on the incidence of nephrotoxicity among patients hospitalized with an infection and treated with aminoglycosides (AGs). Secondary goals of the study will be as follows: comparison of the mortality rates, and length of hospitalization among patients treated with N-acetylcysteine compared to the control group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients hospitalized with presumptive gram-negative infection, as assessed by the treating house staff and requiring gentamycin therapy according to an infectious disease specialist decision.
  • Aged between 18 and
  • Recruitment time between starting gentamycin therapy and initiation of the study intervention will be less than 24 hours.
  • Signed informed consent.

排除标准

  • Any known allergy or intolerance to one of the medications in the AG group.
  • Any known allergy or intolerance to N-acetylcysteine.
  • Any immunosuppressive therapy excluding steroid therapy.
  • HIV infection.
  • Non-sepsis-related neutropenia.
  • An estimated creatinine clearance of less than 30 mL/min.
  • Acute renal failure defined as elevation in creatinine level of 0.5 mg/dL above the patient's baseline.

结局指标

主要结局

The decrease in glomerular filtration rate (GFR)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Victor Novack

Head, Clinical research center

Soroka University Medical Center

研究点 (2)

Loading locations...

相似试验